ERBB2 and breast carcinoma: Majority (91.3%) of patients underwent a biopsy at the time of metastatic breast cancer diagnosis, which was used for receptor status identification including HER2 status by immunohistochemistry (IHC), and the remainder had receptor status determined from primary tumor pathology.